Cationic nanocapsules as a non-viral vector for CRISPR-Cas9–based genome editing for myocilin associated glaucoma therapy
Karthikeyan Kesavan , Virendra Kumar , Jothimani Rajeswari , Charles Searby , Val C. Sheffield
AIMS Molecular Science ›› 2025, Vol. 12 ›› Issue (4) : 341 -356.
Our aim of this work was the development of positively charged D-α-tocopheryl glycol succinate 1000 (TPGS)-chitosan nanocapsules (TCNs) as a non-viral vector for effective genome editing. A two-step process was used to create cationic TCNs. TPGS was initially esterified using succinic anhydride to add a carboxylic acid group. Then, using a complex coacervation technique, ionic cross-linking was used to join the activated TPGS with chitosan. Fourier transform infrared (FTIR) spectroscopy was used to validate the synthesis of TCNs. A gel retardation experiment was performed to evaluate TCNs/pDNA complex entrapments at various N/P ratios (2:1, 5:1, and 10:1). The physicochemical properties of the TCNs/pDNA complex were identified. Plasmid DNA was protected from DNase I activity through TCN complexation. HEK293 and GTM3 cell lines were used to test in vitro transfection efficiency. At N/P 5:1, TCNs/pDNA exhibited the maximum transfection efficiency, which was comparable to Lipofectamine 3000™. Cellular uptake and localization studies confirmed effective delivery of Cas9-GFP plasmids using TCNs. A T7 endonuclease mismatch detection assay further demonstrated effective targeting and editing of the MYOC gene in HEK293 cells using our TCN delivery system. Based on these findings, cationic TCNs represent a promising non-viral gene delivery platform for potential treatment of myocilin-associated glaucoma.
CRISPR / Glaucoma / Non-viral / Myocilin / Chitosan / TPGS
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
/
| 〈 |
|
〉 |